Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Ibrutinib Off-Target Inhibition Inhibits Antibody-Dependent Cellular Phagocytosis but Not Efferocytosis of CLL Cells

Charles C. Chu, PhD, Jonathan J. Pinney, PhD, Sara K. Blick-Nitko, MS, Andrea M. Baran, MS, Derick R. Peterson, PhD, Hannah E. Whitehead, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Paul M. Barr, MD, Karl R. VanDerMeid, BS, Michael Rusty Elliott, PhD, Clive S. Zent, MD

Blood (2020) 136 (Supplement 1): 45.

https://doi.org/10.1182/blood-2020-139483

Published: 2020

Journal Articles

Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia

Jennifer A. Woyach, MD, James S. Blachly, MD, Kerry A. Rogers, MD, Seema A Bhat, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Mojgan Jianfar, MD, Gerard Lozanski, MD, David M. Weiss, Barbara L. Andersen, PhD, Priti Patel, MD, Veerendra Munugalavadla, PhD, Anna Butturini, MD, Yan Xu, Min Hui Wang, PhD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-136317

Published: 2020

Journal Articles

Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice

Charles C. Chu, PhD, Jonathan J. Pinney, MS, Karl R. VanDerMeid, BS, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Paul M. Barr, MD, Michael Rusty Elliott, PhD, Clive S Zent, MD

Blood (2019) 134 (Supplement_1): 682.

https://doi.org/10.1182/blood-2019-124901

Published: 2019

Journal Articles

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Blood (2019) 134 (Supplement_1): 31.

https://doi.org/10.1182/blood-2019-128404

Published: 2019

Journal Articles

High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)

Elena Bibikova, Brian Law, Tracy Clevenger, PhD, Jean Cheung, MS, Gary De Jesus, Michael Gulrajani, Kyoko Yamaguchi, Phuong Do, Kathleen Burke, PhD, Graham Brock, PhD, Veerendra Munugalavadla, PhD, Melanie M. Frigault, PhD, John C. Byrd, MD, Richard R. Furman, MD, Jennifer R. Brown, MD PhD, Todd Covey

Blood (2019) 134 (Supplement_1): 2571.

https://doi.org/10.1182/blood-2019-128872

Published: 2019

Journal Articles

A Critical Role for PIM2 Kinase in Multiple Myeloma Through NF-κB Activation

Veerendra Munugalavadla, PhD, Leanne Berry, Jae Chang, Geoffrey Del Rosario, Jake Drummond, Changchun Du, Karen Fitzgerald, Lori S Friedman, Stephen E Gould, Heather Maecker, John Moffat, Dionysos Slaga, Xiaojing Xiaojing, Kristina West, Shang-Fan Yu, Allen J. Ebens, PhD

Blood (2011) 118 (21): 1839.

https://doi.org/10.1182/blood.V118.21.1839.1839

Published: 2011

Journal Articles

KIT Induced Myeloproliferative Disease Is Dependent on PI3Kinase and SHP2 Phosphatase: Identification of SHP2 As a Druggable Target for Treating MPD and AML

Peilin Ma, MD, PhD, Raghuveer Mali, Ph.D., Li-Fan Zeng, PhD, Holly Martin, Baskar Ramdas, Ph.D., Yantao He, PhD, Emily Sims, Joydeep Ghosh, Ph.D, Sarah C Nabinger, Shuo Li, Veerendra Munugalavadla, PhD, Anindya Chatterjee, PhD, George Sandusky, MD, Andrew Craig, PhD, Kevin D. Bunting, PhD, Gen-Sheng Feng, Rebecca J. Chan, MD, PhD, Zhong-Yin Zhang, PhD, Reuben Kapur, PhD

Blood (2011) 118 (21): 868.

https://doi.org/10.1182/blood.V118.21.868.868

Published: 2011

Journal Articles

A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: Mechanism of Action and Signal Transduction Studies

Blood (2010) 116 (21): 4084.

https://doi.org/10.1182/blood.V116.21.4084.4084

Published: 2010

Journal Articles

A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: The Biology of Single Agent and PI3K/AKT/mTOR Combination Activity

Blood (2010) 116 (21): 3001.

https://doi.org/10.1182/blood.V116.21.3001.3001

Published: 2010

Journal Articles

The PI3K Inhibitor GDC-0941 Synergizes with Standard of Care Therapies to Induce Growth Inhibition and Apoptosis of Multiple Myeloma Cells.

Veerendra Munugalavadla, PhD, Leanne Berry, Changchun Du, BM, BS, Sanjeev Mariathasan, Dion Slaga, Laura Sun, Marta Chesi, Peter Leif Bergsagel, MD, Allen J. Ebens, PhD

Blood (2009) 114 (22): 3788.

https://doi.org/10.1182/blood.V114.22.3788.3788

Published: 2009

Journal Articles

ROCKI Regulates Growth, Maturation and Migration of Mast Cells.

Veerendra Munugalavadla, PhD, Emily Sims, BS, Jianjian Shi, PhD, Lei Wei, MD/PhD, Reuben Kapur, PhD

Blood (2007) 110 (11): 2191.

https://doi.org/10.1182/blood.V110.11.2191.2191

Published: 2007

Journal Articles

Requirement for p85α Regulatory Subunit of Class IA PI3Kinase and Rac2 GTPase in Myeloproliferative Disease Driven by Activation Loop Mutant of KIT.

Veerendra Munugalavadla, PhD, Emily C. Sims, Stephen D. Lenz, Reuben Kapur

Blood (2007) 110 (11): 89.

https://doi.org/10.1182/blood.V110.11.89.89

Published: 2007

Journal Articles

p85α Regulatory Subunit of Class IA PI-3Kinase Regulates Osteoclast Function(s) and Bone Mass.

Veerendra Munugalavadla, PhD, Emily Sims, BS, David A. Ingram, MD, Alexander Robling, PhD, Reuben Kapur, PhD

Blood (2005) 106 (11): 2223.

https://doi.org/10.1182/blood.V106.11.2223.2223

Published: 2005

Journal Articles

Gleevec Resistant Activating Mutation of c-Kit (D816V) Demonstrates Ligand Independent Growth and Promiscuous Cooperation with Multiple Cytokine Receptors Via the p85α Subunit of Class IA PI-3Kinase.

Veerendra Munugalavadla, PhD, Emily Sims, BS, Jovencio Borneo, BS, Reuben Kapur, PhD

Blood (2005) 106 (11): 3530.

https://doi.org/10.1182/blood.V106.11.3530.3530

Published: 2005

NARROW

Ibrutinib Off-Target Inhibition Inhibits Antibody-Dependent Cellular Phagocytosis but Not Efferocytosis of CLL Cells

Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia

Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)

A Critical Role for PIM2 Kinase in Multiple Myeloma Through NF-κB Activation

KIT Induced Myeloproliferative Disease Is Dependent on PI3Kinase and SHP2 Phosphatase: Identification of SHP2 As a Druggable Target for Treating MPD and AML

A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: Mechanism of Action and Signal Transduction Studies

A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: The Biology of Single Agent and PI3K/AKT/mTOR Combination Activity

The PI3K Inhibitor GDC-0941 Synergizes with Standard of Care Therapies to Induce Growth Inhibition and Apoptosis of Multiple Myeloma Cells.

ROCKI Regulates Growth, Maturation and Migration of Mast Cells.

Requirement for p85α Regulatory Subunit of Class IA PI3Kinase and Rac2 GTPase in Myeloproliferative Disease Driven by Activation Loop Mutant of KIT.

p85α Regulatory Subunit of Class IA PI-3Kinase Regulates Osteoclast Function(s) and Bone Mass.

Gleevec Resistant Activating Mutation of c-Kit (D816V) Demonstrates Ligand Independent Growth and Promiscuous Cooperation with Multiple Cytokine Receptors Via the p85α Subunit of Class IA PI-3Kinase.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only